menu
    • menu
    [{"orgOrder":0,"company":"Astellas Pharma","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ UMass Chan Medical School","highestDevelopmentStatusID":"2","companyTruncated":"Astellas Pharma \/ UMass Chan Medical School"},{"orgOrder":0,"company":"Eisai","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Washington University School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Eisai \/ Washington University School of Medicine"},{"orgOrder":0,"company":"EditForce","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"RNA","graph1":"Neurology","graph2":"Discovery","graph3":"EditForce","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EditForce \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"2","companyTruncated":"EditForce \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Axil Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LUCA Science \/ Axil Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"LUCA Science \/ Axil Capital Partners"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Schrodinger","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Otsuka Pharmaceutical \/ Schrodinger","highestDevelopmentStatusID":"2","companyTruncated":"Otsuka Pharmaceutical \/ Schrodinger"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie Inc"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JCR Pharmaceuticals \/ Angelini Pharma","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Angelini Pharma"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Luxna Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Luxna Biotech \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Luxna Biotech \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"SBI Investment Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Disulfide Rich Peptides","moa":"Ion Channel","graph1":"Neurology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veneno Technologies \/ SBI Investment Co","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Technologies \/ SBI Investment Co"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Peptide","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Discovery","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PeptiDream \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ Takeda Pharmaceutical"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Astellas Pharma

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : UMass Chan Medical School

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Astellas Announces Sponsored Research Agreement with UMass Chan Medical School

                            Details : The agreement aims to proceed with research for an adeno-associated virus (AAV) vector mediated gene therapy for the treatment of Alexander disease, a fatal, ultra-rare disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 20, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : UMass Chan Medical School

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            JCR Pharmaceuticals

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            JCR Pharmaceuticals

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            JCR Pharmaceuticals Achieves Milestone in Collaboration with Alexion Using J-Brain Cargo

                            Details : The collaboration aims to develop an undisclosed initial therapeutic molecule that applies JCR’s proprietary J-Brain Cargo®, BBB penetration technology, for a neurodegenerative disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 19, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            JCR Pharmaceuticals

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            JCR Pharmaceuticals

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Modalis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Modalis and JCR Pharmaceuticals Enter into Joint Research Agreement

                            Details : Modalis and JCR Pharmaceuticals aim to establish new gene therapies for undisclosed CNS diseases by applying J-Brain Cargo®, JCR Pharmaceuticals’ proprietary technology for crossing the blood-brain barrier, and CRISPR-GNDM®, Modalis proprietary epige...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 12, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Modalis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            JCR Pharmaceuticals

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            JCR Pharmaceuticals

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Angelini Pharma

                            Deal Size : $505.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Angelini Pharma and JCR Pharmaceuticals Announce Global Collaboration for the Development and Commercializatio...

                            Details : The collaboration combines Angelini Pharma’s expertise in neurological diseases with JCR Pharmaceuticals’ J-Brain Cargo®, blood-brain barrier penetrating technology to develop highly innovative brain-penetrant biologic therapeutics in epilepsy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Angelini Pharma

                            Deal Size : $505.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Otsuka Pharmaceutical

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            Otsuka Pharmaceutical

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Schrodinger

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

                            Details : Under the terms of the agreement, Schrödinger will be responsible for drug design through lead optimization and Otsuka will be responsible for all other drug discovery and clinical development activities, with the aim of rapidly expanding Otsuka's R&D p...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Schrodinger

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            JCR Pharmaceuticals

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            JCR Pharmaceuticals

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a T...

                            Details : Under the agreement, the two companies will begin research and development of new treatments using the J-Brain Cargo®, blood-brain barrier (“BBB”) penetration technology, in combination with an undisclosed effector molecule for the treatment of a ne...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 04, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eisai

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            Eisai

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Washington University School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eisai And Washington University School Of Medicine In St. Louis Enter Into Comprehensive Research Collaboratio...

                            Details : The collaboration strategically combines Washington University scientists’ expertise in the fundamental and clinical research in neurodegenerative diseases, such as dementia, with Eisai’s extensive experience in drug discovery and development.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 14, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Washington University School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            EditForce

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            EditForce

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Mitsubishi Tanabe Pharma

                            Deal Size : $145.7 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement

                            Details : In this alliance, MTPC and EditForce aim to create potential novel pharmaceuticals for the specific CNS disease by utilizing the drug R&D. EditForce will proceed with R&D of pharmaceuticals using PPR protein platform technology.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 27, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Mitsubishi Tanabe Pharma

                            Deal Size : $145.7 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Luxna Biotech

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            Luxna Biotech

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $86.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Luxna Announces Technology License Agreement With Takeda

                            Details : Under the license agreement, Takeda will have the exclusive right to develop and commercialize nucleic acid­based therapies using Luxna XNAs Technology for specified targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 24, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $86.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sosei Heptares

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            Sosei Heptares

                            Japan arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : AbbVie Inc

                            Deal Size : $1,280.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Me...

                            Details : New strategic collaboration of AbbVie leverages Sosei Heptares’ StaR® technology and SBDD platform to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological diseas...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $40.0 million

                            February 08, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : AbbVie Inc

                            Deal Size : $1,280.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth